Table II.
Baseline characteristics of patients receiving the three treatment protocols.
| Group 1 (antibiotic + CE) |
Group 2 (CE in monotherapy) |
Group 3 (antibiotic in monotherapy) |
All patients |
|
|---|---|---|---|---|
| Patients, N (%) | 128 (40.3%) | 90 (28.4%) | 99 (31.3%) | 317 (100%) |
| Gender (female), N (%) | 74 (57.8%) | 53 (58.9%) | 55 (55.6%) | 182 (57.4%) |
| Age, years (mean±SD) | 49.7 ± 4.7 | 47.3 ± 5.3 | 42.3 ± 4.9 | 46.4 ± 5.0 |
| TNSS, VAS (mean±SD) | 8.80 ± 0.29* | 7.93 ± 0.25 | 8.23 ± 0.34 | 8.32 ± 0.29 |
| EAS, middle meatus discharge (mean±SD) | 2.35 ± 0.09 | 2.07 ± 0.10 | 2.11 ± 0.12 | 2,18 ± 0.1 |
| EAS, middle meatus mucosal edema (mean±SD) | 2.55 ± 0.07 | 2.49 ± 0.08 | 2.59 ± 0.11 | 2.54 ± 0.09 |
CE, Cyclamen europaeum; TNSS, Total Nasal Symptom Score; EAS, Endoscopic Assessment Score; SD, standard deviation; VAS, Visual Analogue Score
*, p < 0.01 vs. group 2.